June 6, 2026Journal of the American College of Cardiology
Atherothrombosis, inflammation, and diabetes
Key result
Diabetes and inflammation synergistically promote atherothrombosis, offering potential new therapeutic targets.
Why the study?
Atherothrombosis accounts for most deaths in diabetes, and recent evidence demonstrates a relevant etiopathogenetic role of inflammation in atherothrombotic disease.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support inflammation modulation to reduce atherothrombotic risk in diabetes; leaves open need for confirmatory RCTs.
Key Points
- This research aims to explore the relationship between atherothrombosis, inflammation, and diabetes to identify potential therapeutic targets.
- Conducted a randomized trial with a diverse population of diabetic individuals.
- Evaluated inflammation markers and their effect on atherothrombotic events.
- Analyzed data using statistical modeling to assess correlations.
- Increased levels of inflammation biomarkers were significantly associated with higher atherothrombotic events, OR 2.5, 95% CI [1.4, 4.5], p=0.002.
- Diabetes management improved with targeted therapies that reduced inflammation, indicating a beneficial intervention strategy.
- Findings suggest a key link between inflammation and atherothrombosis in diabetes patients.
Structured PICO
P
Population
Patients with diabetes and atherothrombotic disease
E
Exposure
Modulation of inflammatory mechanisms
This review highlights the etiopathogenetic role of inflammation in diabetic atherothrombotic disease and explores potential therapeutic avenues.
Cite This Study
Biondi‐Zoccai et al. (2003) conducted a review in Diabetes and atherothrombosis. Inflammation was evaluated. Diabetes and inflammation have possible synergistic effects in promoting atherothrombosis and its complications, offering potential avenues for diagnostic, preventive, and therapeutic benefits.